Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?
This article was originally published in The Tan Sheet
Executive Summary
A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei